The UK and US have established a key bilateral deal that will guarantee zero duties on British medicine shipments going into the American market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has pledged to raise spending on medicines through the NHS. This move secures that duties on these crucial products will remain at nothing for a timeframe of the next three years.
This agreement is in response to previous warnings to significantly raise duties on patented pharmaceutical products, with increases floated up to 100%.
"This agreement between the UK strengthens the global environment for cutting-edge drugs and establishes much-needed equity to American-British medicine commerce," a release said.
Trade Significance
Drugs represent one of the Britain's most significant goods shipped to the United States, which is clearly the primary market for major British pharmaceutical firms.
Trade data indicate that in the 12 months prior to the third quarter, the UK shipped drugs worth over eleven billion pounds to the US. This value accounted for nearly one-fifth of total UK exports in that span.
"This deal secures work, stimulates funding and facilitates the UK to emerge as a international leader for life sciences," the Business and Trade Secretary commented.
Specific NHS Changes
The agreement involves several specific pledges from the British government:
- Price Threshold Increase: The UK will raise the price threshold at which it judges new therapies to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a target to raise overall public funding on treatments from 0.3% of the national economy to 0.6% over the next decade.
- Rebate Cap: The sum manufacturers must pay back to the NHS to control costs will be capped at fifteen percent. Previously, repayments exceeded twenty percent.
Recent Tensions
This agreement takes place against a protracted dispute between the drug companies and the British authorities over medicine costs and NHS adoption.
These tensions were intensified by claims that US customers were charged several times more for the equivalent treatments than people in the other developed nations.
Over the last 18 months, several large drug company projects in the UK have been paused or cancelled, while substantial funding commitments have been announced toward US facilities.
A senior figure acknowledged that the NHS had to increase expenditure on drugs, noting that its spending on drugs had shrunk as a percentage of its resources over the last ten years.
